nach oben

Reactions Weekly

Erschienen in:

01.06.2023 | Case report

Antineoplastics/unspecified growth-factor

Lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Rai M, et al. Likelihood of Successful Mobilization with Cyclophosphamide after Failure of Growth Factor Mobilization in Patients with Multiple Myeloma. Transplantation and Cellular Therapy 29: S182-S183 abstr. 236, No. 2, 2023. Available from: URL: http://doi.org/10.1016/S2666-6367%2823%2900305-6 [abstract]

Titel: Antineoplastics/unspecified growth-factor
Lack of efficacy: case report
Publikationsdatum: 01.06.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-41731-2

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Antineoplastics/unspecified growth-factor

Lack of efficacy: case report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Apixaban is safest DOAC in terms of non-major bleeding

Carboplatin/pembrolizumab

Hydrocortisone

Multiple drugs

Anakinra/hydroxychloroquine

Paclitaxel